The goal of VascuBone is to develop a "tool box" for bone regeneration, which on one hand fulfills basic requirements and
on the other hand is freely combinable with what is needed in the respective patient's situation. The tool box will include a
variation of biocompatible biomaterials and cell types, FDA approved growth factors, material modification technologies,
simulation and analytical tools like molecular imaging based in vivo diagnostics which can be combined for the specific
medical need. This tool box will be used to develop translational approaches for regenerative therapies of three different
types of bone defects. The chosen bone diseases differ in their requirements, to ensure a successful implementation and
translation. Additionally this implementation strategy is characterized by high complexity to remove bottlenecks and
limitations of bone regeneration identified in the clinical setting. Therefore definite quality criteria have to be evaluated
concerning an optimal stem cell source/subpopulation as well as GF concentrations and their bioactivity in vivo. Furthermore
quantitative evaluation will focus on the definition of differences between stem cell populations responsible for bone
regeneration in young and old people, as a prerequisite for the development of regenerative therapies for the ageing European
|New VascuBone video
Heike Walles, coordinator of the European research project VascuBone, believes that her method of combining human cells with scaffolds and bone substitutes could become a routine procedure in the future and provide a perfect alternative to the current best practices.
More info in Media Centre
Considering a successful and prompt approval of the biomaterial, for each clinical application a minimum of modification steps in daily routine must be identified. The road map of the project and clinical trials contains pre-determined milestones, to ensure efficacy, safety, and immunological acceptance of the implant. The efficacy is quantified by high innovative MRI and PET/CT technology which is able to demonstrate the regenerative effect of biomaterials and cells in vivo. Based on the clinical data the proposal as "Advanced Therapeutical Medicinal Product" will be submitted to the European Medicines Agency at the end of the project.
|The research leading to these results has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement n°242175|